Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kalos

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Science Translational Medicine|June 18, 2010
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphomaDavid L DiGiusto, Amrita Krishnan, Lijing Li, et al.
Journal for Immunotherapy of Cancer|May 2, 2018
Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054Yiwen Li, Carmine Carpenito, George Wang, et al.
Journal for Immunotherapy of Cancer|June 6, 2018
Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054Yiwen Li, Carmine Carpenito, George Wang, et al.
Science Translational Medicine|May 4, 2012
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cellsJohn Scholler, Troy L Brady, Gwendolyn Binder-Scholl, et al.
Journal for Immunotherapy of Cancer|June 6, 2018
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockadeRikke B Holmgaard, David A Schaer, Yanxia Li, et al.
Cancer Immunology, Immunotherapy : CII|December 25, 2012
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumorsEmmet McCormack, Katherine J Adams, Namir J Hassan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2013
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedsideCheryl Lai-Lai Chiang, Lana E Kandalaft, Janos Tanyi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2016
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell LymphomaMarco Ruella, Saad S Kenderian, Olga Shestova, et al.
Cytotherapy|April 7, 2024
Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related productsMark D Stewart, Michael Kalos, Vicki Coutinho, et al.
Journal of Translational Medicine|March 17, 2012
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancerDavid F Stroncek, Carolina Berger, Martin A Cheever, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Science Translational Medicine|June 18, 2010
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphomaDavid L DiGiusto, Amrita Krishnan, Lijing Li, et al.
Journal for Immunotherapy of Cancer|May 2, 2018
Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054Yiwen Li, Carmine Carpenito, George Wang, et al.
Journal for Immunotherapy of Cancer|June 6, 2018
Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054Yiwen Li, Carmine Carpenito, George Wang, et al.
Science Translational Medicine|May 4, 2012
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cellsJohn Scholler, Troy L Brady, Gwendolyn Binder-Scholl, et al.
Journal for Immunotherapy of Cancer|June 6, 2018
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockadeRikke B Holmgaard, David A Schaer, Yanxia Li, et al.
Cancer Immunology, Immunotherapy : CII|December 25, 2012
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumorsEmmet McCormack, Katherine J Adams, Namir J Hassan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2013
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedsideCheryl Lai-Lai Chiang, Lana E Kandalaft, Janos Tanyi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2016
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell LymphomaMarco Ruella, Saad S Kenderian, Olga Shestova, et al.
Cytotherapy|April 7, 2024
Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related productsMark D Stewart, Michael Kalos, Vicki Coutinho, et al.
Journal of Translational Medicine|March 17, 2012
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancerDavid F Stroncek, Carolina Berger, Martin A Cheever, et al.
Pageof 8